First Time Loading...
G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 836.25 INR 0.63% Market Closed
Updated: May 31, 2024

Glenmark Life Sciences Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Life Sciences Ltd
Cash & Cash Equivalents Peer Comparison

Comparables:
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
T
TORNTPHARM

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Cash & Cash Equivalents
₹2.8B
CAGR 3-Years
35%
CAGR 5-Years
168%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash & Cash Equivalents
₹7.1B
CAGR 3-Years
-22%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash & Cash Equivalents
₹8.7B
CAGR 3-Years
-15%
CAGR 5-Years
7%
CAGR 10-Years
17%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash & Cash Equivalents
₹72.2B
CAGR 3-Years
11%
CAGR 5-Years
-6%
CAGR 10-Years
1%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Cash & Cash Equivalents
₹11.1B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
7%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash & Cash Equivalents
₹5.6B
CAGR 3-Years
6%
CAGR 5-Years
-11%
CAGR 10-Years
-4%

See Also

What is Glenmark Life Sciences Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.8B INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Cash & Cash Equivalents amounts to 2.8B INR.

What is Glenmark Life Sciences Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
168%

Over the last year, the Cash & Cash Equivalents growth was 0%. The average annual Cash & Cash Equivalents growth rates for Glenmark Life Sciences Ltd have been 35% over the past three years , 168% over the past five years .